Foley Todd, DIR, reported a transaction classified as C at Aktis Oncology, Inc. involving 597391.000000 shares. Reported holdings after the transaction were 597391.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
No officer title
The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 10,988 by MPM Asset Ma…
BV 2018(B). BV 2018 LLC is the manager of AM BV2018. The Reporting Person is a managing director of BV 2018 LLC.
Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into share…
The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
The shares are held as follows: 556,810 by BV 2018, 29,593 by BV 2018(B) and 10,988 by AM BV2018.
The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B) and 49,452 by AM BV2018.
The shares are held as follows: 3,062,458 by BV 2018, 162,763 by BV 2018(B) and 60,440 by AM BV2018.
The shares of common stock were issued upon conversion as follows: 668,173 by BV 2018, 35,512 by BV 2018(B) and 13,187 by AM BV2018.
The shares are held as follows: 3,730,631 by BV 2018, 198,275 by BV 2018(B) and 73,627 by AM BV2018.
The shares were purchased as follows: 219,897 by BV 2018, 8,689 by BV 2018(B) and 4,284 by AM BV2018.
The shares are held as follows: 3,950,528 by BV 2018, 206,964 by BV 2018(B) and 77,911 by AM BV2018.
0 other filings
0 recent txs